Guardant Health (GH) vs GRAIL (GRAL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Guardant Health (GH) has outperformed GRAIL (GRAL) over the past year, gaining 165.3% versus a gain of 111.6%. Guardant Health is the larger company by market cap ($22.59 billion vs $5.94 billion), about 3.8 times the size. Guardant Health converts more of its revenue into profit, with a net margin of -42.4% versus -277.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GH | GRAL |
|---|---|---|
| Share price | $168.33 | $132.90 |
| Market cap | $22.59B | $5.94B |
| 1-day change | -1.38% | -3.19% |
| YTD return | +64.80% | +55.28% |
| 1-year return | +165.34% | +111.56% |
| 5-year return | +65.68% | — |
| EPS (TTM) | $-3.45 | $-9.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $982.02M | $147.17M |
| Revenue growth (YoY) | +32.88% | +17.18% |
| Net income (latest FY) | $-416.28M | $-408.35M |
| Gross margin | 64.46% | — |
| Operating margin | -44.53% | -381.98% |
| Net margin | -42.39% | -277.47% |
| 52-week high | $191.05 | $166.48 |
| 52-week low | $61.00 | $41.50 |
| Distance from 52-week high | -11.89% | -20.17% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +18.72% | -15.43% |
| Average volume | 2.01M | 930.77K |
| Shares outstanding | 134.20M | 44.67M |
| Employees | 2,490 | 910 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Guardant Health is about 3.8 times larger than GRAIL by market value ($22.59B vs $5.94B).
- GH has outperformed GRAL by 53.8 percentage points over the past year.
- Guardant Health is more profitable, keeping -42.4 cents of every revenue dollar as net income versus -277.5 cents for GRAIL.
- Guardant Health grew revenue faster in its latest fiscal year (+32.88% vs +17.18%).
About Guardant Health
GH stock →Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights.
Health Care · Medical Specialities · 2,490 employees
About GRAIL
GRAL stock →GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer.
Health Care · Medical Specialities · 910 employees
GH vs GRAL FAQ
Which is bigger, Guardant Health or GRAIL?
Guardant Health (GH) is larger, with a market capitalization of $22.59B compared with $5.94B for GRAIL (GRAL).
Which stock has performed better over the past year, GH or GRAL?
GH returned +165.34% over the past 12 months, compared with +111.56% for GRAL (price return, excluding dividends). Past performance does not predict future results.
Are Guardant Health and GRAIL in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.